期刊文献+

阿托伐他汀联合中医中药改善慢性心力衰竭预后的临床观察

Clinical Observation of Atorvastatin Combined with Traditional Chinese Medicine to Improve the Prognosis of Patients with Chronic Heart Failure
下载PDF
导出
摘要 目的:探讨阿托伐他汀联合中医中药改善慢性心力衰竭预后的效果。方法:将100例慢性心力衰竭心功能NY-HA分级Ⅱ-Ⅳ级的患者随机分为对照组48例与治疗组52例,对照组给予常规治疗,包括洋地黄、血管紧张素酶抑制剂、β受体抑制剂、利尿剂等;治疗组在对照组治疗的基础上,给予口服阿托伐他汀,同时口服中药。所有患者治疗8周后复查。结果:治疗后,治疗组总有效率78.8%,高于对照组的45.8%,差异有统计学意义(P〈0.01),且治疗组死亡率显著低于对照组,差异有统计学意义(P〈0.01)。治疗后,两组TC、LDL-C、CRP均低于治疗前,LVEF高于治疗前;治疗组TC、LDL-C、CRP均低于对照组,LVEF高于对照组,差异均有统计学意义(P〈0.05)。两组住院次数、住院时间比较差异无统计学意义(P〉0.05)。结论:应用阿托伐他汀联合中医中药治疗心力衰竭患者方法简便、疗效好,可显著提高患者的治疗效果,有临床推广应用价值。 Objective: To investigate the effect of Atorvastatin combined with traditional Chinese medicine in improving the prognosis of patients with chronic heart failure.Method: 100 cases of chronic heart failure patients whose cardiac function NY-HA grade was II-IV grade were randomly divided into the control group (48 cases) and treatment group (52 cases).The control group was treated with conventional treatment, including Digitalis, angiotensin enzyme inhibitor, beta blockers and diuretics.The treatment group on the basis of the control group was given oral Atorvastatin and traditional Chinese medicine.Mter 8 weeks of treatment, all patients were reviewed.Result: After treatment, the total effective rate of the treatment group was 78.8%, higher than 45.8% of the control group, the difference was statistically significant(P〈0.01), and the death rate of the treatment group was significantly lower than that of the control group, the difference was statistically significant(P〈0.01).After treatment, the TC, LDL-C and C-reactive protein of the two groups were lower than before treatment, and the left ventricular ejection fraction(LVEF) was higher than before treatment, the TC, LDL-C and C-reactive protein of the treatment group were lower than those of the control group, and the left ventricular ejection fraction(LVEF) was higher than that of the control group, the differences were statistically significant(P〈0.05).There was no statistically significant difference in the number of times of hospitalization and the total length of stay between the two groups(P〉0.05).Conclusion: The application of Atorvastatin combined with traditional Chinese medicine in the treatment of chronic heart failure is simple and effective, it can significantly improve the treatment effect, which has the value of clinical application.
机构地区 曹县中医院
出处 《中外医学研究》 2016年第24期4-6,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 阿托伐汀 中医中药 慢性心力衰竭 心室重塑 疗效 预后 Atorvastatin Traditional Chinese medicine Chronic heart failure Ventricular remodeling Curative effect Prognosis
  • 相关文献

参考文献10

二级参考文献102

  • 1黄樱硕,李敏.慢性心力衰竭合并贫血的研究进展[J].中华临床医师杂志(电子版),2011,5(21):6378-6382. 被引量:7
  • 2丁亚媛,杨志健,贾恩志,朱铁兵,王连生,陈波,曹克将,马文珠.C-反应蛋白含量与冠状动脉狭窄程度关系的研究[J].南京医科大学学报(自然科学版),2006,26(6):441-444. 被引量:5
  • 3Horwich TB, Patel J, Mac Lellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left vcnlricu- far dysfunction, and incrcasedmortality rates in advanced heart fail- ure[J]. Circulation, 2003, 108(7): 833-838.
  • 4Guerra S, Leri A, Wang X, et al. Myoeyte death in the failing hu- man heart is gender dependent[J]. Circ Res, 1999, 85(9): 856-866.
  • 5Go AS, Lee WY, Yang J, ctal. Statin therapy and risks for death and hospitalization in chronic heart failum[J].JAMA, 2006, 296 (17): 2105-2111.
  • 6Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associ- ated with improved survival in ischemic and non-ischemic heart fail- le[J]. JAm Coil Cardiol, 2004, 43(4): 642-648.
  • 7Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvas- tatin in older patients with systolic heart failure[J]. N Engl I Med, 2007, 357(22): 2248-2261.
  • 8Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect ofro- suvastatin in patients with chronic heart failure (the GISSI-HF tri- al): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008, 372(9645):1231-1239.
  • 9Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure [J]. Am J Cardiol, 2009, 104(1 2): 1708-1716.
  • 10McMurray JJ, Kjekshus J, Gullestad L, et al. Effects of statin thera- py according to plasma high-sensitivity C-reactive protein concen- tration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis [J]. Circulation. 2009, 120(22): 2188-2196.

共引文献203

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部